French Patient-Reported Experience of Diagnosis, Management and Burden of Neuroendocrine Tumors

References

• RindiG, KlimstraDS, Abedi-ArdekaniB et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod. Pathol. 31(12), 1770–1786 (2018).
   Google Scholar
• VinikAI, ChayaC. Clinical presentation and diagnosis of neuroendocrine tumors. Hematol. Oncol. Clin. North Am. 30(1), 21–48 (2016).
   PubMed Web of Science ®Google Scholar
• CaplinME, BaudinE, FerollaP et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann. Oncol. 26(8), 1604–1620 (2015).
   PubMed Web of Science ®Google Scholar
• TuragaKK, KvolsLK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J. Clin. 61(2), 113–132 (2011).
   PubMed Web of Science ®Google Scholar
• ScoazecJY, CouvelardA, MongesG et al. Professional practices and diagnostic issues in neuroendocrine tumour pathology: results of a prospective one-year survey among French pathologists (the PRONET Study). Neuroendocrinology 105(1), 67–76 (2017).
   PubMed Web of Science ®Google Scholar
• LepageC, BouvierAM, PhelipJM et al. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 53(4), 549–553 (2004).
   PubMed Web of Science ®Google Scholar
• SinghS, GranbergD, WolinE et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J. Glob. Oncol. 3(1), 43–53 (2017).
   PubMedGoogle Scholar
• WolinEM, LeydenJ, GoldsteinG et al. Patient-reported experience of diagnosis, management, and burden of neuroendocrine tumors: results from a large patient survey in the United States. Pancreas 46(5), 639–647 (2017).
   PubMed Web of Science ®Google Scholar
• CascianoR, WangX, SternL et al. International practice patterns and resource utilization in the treatment of neuroendocrine tumors. Pancreas 42(2), 339–347 (2013).
   PubMed Web of Science ®Google Scholar
• PlanteA, BaudinE, DoCao C et al. Patient-reported tolerance in treatments approved in neuroendocrine tumors: a national survey from the French Group of Endocrine Tumors. Clin. Res. Hepatol. Gastroenterol. 42(2), 153–159 (2018).
   PubMed Web of Science ®Google Scholar
• StrosbergJR, HalfdanarsonTR, BellizziAM et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas 46(6), 707–714 (2017).
   PubMed Web of Science ®Google Scholar
• BeaumontJL, CellaD, PhanAT et al. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas 41(3), 461–466 (2012).
   PubMed Web of Science ®Google Scholar
• FrojdC, LarssonG, LampicC, von EssenL. Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study. Health Qual. Life Outcomes 5, 18 (2007).
   PubMed Web of Science ®Google Scholar
• HauglandT, VatnMH, VeenstraM et al. Health related quality of life in patients with neuroendocrine tumors compared with the general Norwegian population. Qual. Life Res. 18(6), 719–726 (2009).
   PubMed Web of Science ®Google Scholar
• ChuangCC, BhurkeS, ChenSY et al. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study. J. Med. Econ. 18(2), 126–136 (2015).
   PubMed Web of Science ®Google Scholar
• MartyR, RozeS, KurthH. Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK. Med. Devices (Auckl). 5, 39–44 (2012).
   PubMedGoogle Scholar
• TandonA, MurrayCJL, LauerJA, EvansDB. Measuring overall health system performance for 191 countries. WHO, Geneva, Switzerland (2000). GPE Discussion Paper Series: No. 30.
   Google Scholar
• GBD2015 Healthcare Access and Quality Collaborators. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet 390(10091), 231–266 (2017).
   PubMed Web of Science ®Google Scholar
• GBD2016 Healthcare Access and Quality Collaborators.Measuring performance on the healthcare access and quality index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet 391(10136), 2236–2271 (2018).
   PubMed Web of Science ®Google Scholar
• SchneiderEC, SarnakDO, SquiresD et al. Mirror, Mirror 2017: international comparison reflects flaws and opportunities for better U.S. Healthcare. The Commonwealth Fund, Washington DC, USA (2017). https://interactives.commonwealthfund.org/2017/july/mirror-mirror/
   Google Scholar
• Global Burden of Disease Health Financing Collaborator Network. Trends in future health financing and coverage: collabfuture health spending and universal health coverage in 188 countries, 2016–40. Lancet 391(10131), 1783–1798 (2018).
   Google Scholar
• BenjaminL, ButhionV, Vidal-TrecanG, BriotP. Impact of the healthcare payment system on patient access to oral anticancer drugs: an illustration from the French and United States contexts. BMC Health Serv. Res. 14, 274 (2014).
   PubMed Web of Science ®Google Scholar
• ChevreulK, BergBringham K, Durand-ZaleskiI, Hernandez-QuevedoC. France. Health system review. Health Syst. Trans. 17(3), 251 (2015).
   Google Scholar